SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
SciSparc announced that its subsidiary NeuroThera Labs has enrolled 26 children in a clinical trial for SCI-210, targeting a total of 60 patients to evaluate the treatment for autism spectrum disorder. The double-blind, placebo-controlled study is assessing the safety and efficacy of the proprietary CBD and CannAmide combination over a 20-week period at Soroka Medical Center in Israel.
Key figures
- Enrolled patients
- 26
- Patient age range
- 5-18
- Target enrollment
- 60
- Treatment duration weeks
- 20
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.